Summary
The NABUCCO trial investigated preoperative combination immunotherapy with ipilimumab and nivolumab at two dose levels in stage III urothelial cancer patients prior to radical cystectomy. As a phase 1B study, the trial assessed the tolerability and activity of this neoadjuvant approach to inform optimal dosing strategies for subsequent clinical development. The work was published in Nature Medicine in 2023 and reflects current interest in checkpoint inhibitor combinations as preoperative treatment in advanced urothelial malignancy.
UK applicability
This trial includes United Kingdom centres and investigates treatment protocols potentially applicable to NHS oncology practice. However, the findings are specific to stage III urothelial cancer and require integration with existing neoadjuvant treatment guidelines before broader implementation in UK clinical practice.
Key measures
Preoperative adverse events, pathological response rates, recurrence-free survival, overall survival, immunological biomarkers
Outcomes reported
The study evaluated safety and efficacy of two different dose levels of combined ipilimumab and nivolumab administered before surgical resection in patients with stage III urothelial cancer.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.